Qurient Therapeutics, a Novartis Venture Fund-backed biotech, has listed on Korea’s Kosdaq stock exchange.
Qurient raised KrW32.5bn ($26m) in its IPO through the sale of 1.5 million shares at KrW21,000 each.
Qurient spun out from Institut Pasteur Korea, a research institute focused on curing infectious diseases, in 2008.